AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30827166 — intervention group
Group type: COMPARATOR
Intervention: Off clamp robotic partial nephrectomy
Number of subjects: 301
Study 30827166 — intervention group
Group type: EXPERIMENTAL
Intervention: Shift robotic partial nephrectomy
Number of subjects: 301
Study 28606216 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.2 g/d n-3 PUFA (3.7 g EPA and 2.5 g DHA)
Number of subjects: 16
Study 28606216 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.1 g/d n-3 PUFA (1.8 g EPA and 1.3 g DHA)
Number of subjects: 16
Study 28606216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 28606216 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.2 g/d n-3 PUFA
Number of subjects: 16
Study 28606216 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.1 g/d n-3 PUFA
Number of subjects: 16
Study 26205382 — intervention group
Group type: EXPERIMENTAL
Intervention: InTen‐S (reduced shrinkage stress resin composite)
Number of subjects: 50
Study 26205382 — intervention group
Group type: COMPARATOR
Intervention: Point 4 (microhybrid resin composite)
Number of subjects: 50
Study 23258767 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 339
Study 23258767 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine
Number of subjects: 339
Study 23258767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 21719095 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day full-dose teplizumab
Number of subjects: 516
Study 21719095 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day low-dose teplizumab
Number of subjects: 516
Study 21719095 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-day full-dose teplizumab
Number of subjects: 516
Study 21719095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study 21719095 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab groups (combined)
Number of subjects: 516
Study 19032601 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (0.5 mg kg(‐1) min(‐1))
Number of subjects: 20
Study 19032601 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arg (0.5 mg kg(‐1) min(1))
Number of subjects: 20
Study 19032601 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (0.03 mg kg(‐1) min(1))
Number of subjects: 20
Study 19032601 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA with saline (150 mL)
Number of subjects: 20
Study 19032601 — intervention group
Group type: COMPARATOR
Intervention: D-Arg
Number of subjects: 20
Study 17368152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin plus glycoprotein IIb/IIIa inhibitors
Number of subjects: 7789
Study 17368152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin alone
Number of subjects: 7789
Study 17368152 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitors
Number of subjects: 7789
Study 15338070 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-/H2-histamine antagonists
Number of subjects: 0
Study 15338070 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine releaser compound 48/80
Number of subjects: 0
Study 15338070 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine injections
Number of subjects: 0
Study 15338070 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11836849 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (40 mg bolus i.v. then 60 mg per day for 48 hours intravenously in glucose infusion)
Number of subjects: 18
Study 11836849 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 18
Study 11836849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9951746 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibody presence in Group 1 (recurrent spontaneous abortion)
Number of subjects: 156
Study 9951746 — intervention group
Group type: COMPARATOR
Intervention: Anticardiolipin antibody presence in Group 2 (fertile women)
Number of subjects: 156
Study 8053971 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide 0.5 once daily morning
Number of subjects: 50
Study 8053971 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolbutamide 0.5 t.i.d.
Number of subjects: 50
Study 8053971 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide 0.005 t.i.d.
Number of subjects: 50
Study 8053971 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibornuride 0.025 t.i.d.
Number of subjects: 50
Study 8053971 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide 0.005 t.i.d.
Number of subjects: 50
Study 8053971 — intervention group
Group type: COMPARATOR
Intervention: Control tests (not specified)
Number of subjects: 50
Study 1960069 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission and postadmission preoperative education
Number of subjects: 40
Study 1960069 — intervention group
Group type: COMPARATOR
Intervention: Routine postadmission preoperative education
Number of subjects: 40
Study 636970 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted manipulation
Number of subjects: 60
Study 636970 — intervention group
Group type: COMPARATOR
Intervention: Free manipulation
Number of subjects: 60
Study 31402142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonheterosexual identity
Number of subjects: 5000
Study 31402142 — intervention group
Group type: COMPARATOR
Intervention: Heterosexual identity
Number of subjects: 5000
Study 29077150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 60
Study 29077150 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 60
Study 26083702 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational skiing intervention (12 weeks)
Number of subjects: 23
Study 26083702 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 23
Study 23216780 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin pad (FP)
Number of subjects: 104
Study 23216780 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 104
Study 21473965 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized risk communication
Number of subjects: 89
Study 21473965 — intervention group
Group type: COMPARATOR
Intervention: Standard risk factor education
Number of subjects: 89
Study 19864467 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 flushing (10L/min for 5 minutes)
Number of subjects: 20
Study 19864467 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CO2 flushing, contained air)
Number of subjects: 20
Study 19864467 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 group
Number of subjects: 20
Study 19864467 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (after knocking on the reservoir at the 14th minute)
Number of subjects: 20
Study 19864467 — intervention group
Group type: COMPARATOR
Intervention: Control group (15th minute)
Number of subjects: 20
Study 19864467 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 group (15th minute)
Number of subjects: 20
Study 17464605 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine, ketorolac, and adrenaline wound infiltration
Number of subjects: 40
Study 17464605 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study 15319604 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc ethylene dicysteine (99mTc‐EC)
Number of subjects: 43
Study 15319604 — intervention group
Group type: COMPARATOR
Intervention: 99mTc dimercaptosuccinic acid (99mTc‐DMSA)
Number of subjects: 43
Study 15319604 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential renal function measurements
Number of subjects: 43
Study 10866903 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (7.2% introduced, increased to 10.8%)
Number of subjects: 20
Study 10866903 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (2.2% introduced, increased to 3.3%)
Number of subjects: 20
Study 8957037 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dextran MW 267,000 (group A)
Number of subjects: 20
Study 8957037 — intervention group
Group type: COMPARATOR
Intervention: Iron dextran MW 96,000 (group B)
Number of subjects: 20
Study 8957037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 20
Study 1325203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 5
Study 3891178 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium bicarbonate dialysis
Number of subjects: 8
Study 3891178 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium acetate dialysis
Number of subjects: 8
Study 3891178 — intervention group
Group type: COMPARATOR
Intervention: Low sodium bicarbonate dialysis
Number of subjects: 8
Study 3891178 — intervention group
Group type: COMPARATOR
Intervention: Low sodium acetate dialysis
Number of subjects: 8
Study 3891178 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate dialysis
Number of subjects: 8
Study 30126687 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser melting (SLM)
Number of subjects: 36
Study 30126687 — intervention group
Group type: COMPARATOR
Intervention: CAD-CAM milling
Number of subjects: 36
Study 30126687 — intervention group
Group type: COMPARATOR
Intervention: Conventional casting
Number of subjects: 36
Study 29603714 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental variable (IV) method
Number of subjects: 0
Study 29603714 — intervention group
Group type: EXPERIMENTAL
Intervention: Anderson‐Rubin test
Number of subjects: 0
Study 29603714 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization studies
Number of subjects: 0
Study 26242466 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg/day for 3 weeks
Number of subjects: 70
Study 26242466 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 70
Study 25163440 — intervention group
Group type: EXPERIMENTAL
Intervention: saffron extract (30 mg/day)
Number of subjects: 68
Study 25163440 — intervention group
Group type: COMPARATOR
Intervention: memantine (20 mg/day)
Number of subjects: 68
Study 22151106 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 120
Study 22151106 — intervention group
Group type: COMPARATOR
Intervention: PLMA
Number of subjects: 120
Study 22151106 — intervention group
Group type: COMPARATOR
Intervention: cLMA
Number of subjects: 120
Study 19381108 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (ARBs)
Number of subjects: 108909
Study 19381108 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment or placebo
Number of subjects: 108909
Study 19381108 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy based on ARBs plus ACE inhibitors
Number of subjects: 108909
Study 17449331 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy education program
Number of subjects: 783
Study 17449331 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 783
Study 15795533 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxifiban (1 mg BID for 9 days)
Number of subjects: 7
Study 15795533 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxifiban (30 nmol/l free acid added to blood from roxifiban-treated subjects)
Number of subjects: 7
Study 11985760 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (n=59)
Number of subjects: 112
Study 11985760 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment (n=53)
Number of subjects: 112
Study 9793620 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine nasal spray and eyedrops
Number of subjects: 102
Study 9793620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil nasal spray and eyedrops
Number of subjects: 102
Study 7892820 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 4120
Study 7892820 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 4120
Study 2798542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 2.5 mg
Number of subjects: 8
Study 2798542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 10 mg
Number of subjects: 8
Study 2798542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine 20 mg
Number of subjects: 8
Study 2798542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2798542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (all doses)
Number of subjects: 8
Study 2798542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (low doses)
Number of subjects: 8
Study 871010 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent study program (ISP)
Number of subjects: 32
Study 871010 — intervention group
Group type: COMPARATOR
Intervention: Lecture discussion (LD) program
Number of subjects: 32
Study 30670264 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power laser auriculotherapy (LA)
Number of subjects: 0
Study 30670264 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splints (OS)
Number of subjects: 0
Study 28265719 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate and vitamin K2
Number of subjects: 2922
Study 28265719 — intervention group
Group type: COMPARATOR
Intervention: Risedronate alone
Number of subjects: 2922
Study 25496265 — intervention group
Group type: EXPERIMENTAL
Intervention: 9% caloric intake from fructose added to milk
Number of subjects: 267
Study 25496265 — intervention group
Group type: COMPARATOR
Intervention: 9% caloric intake from glucose added to milk
Number of subjects: 267
Study 25496265 — intervention group
Group type: EXPERIMENTAL
Intervention: 18% caloric intake from high fructose corn syrup added to milk
Number of subjects: 267
Study 25496265 — intervention group
Group type: COMPARATOR
Intervention: 18% caloric intake from sucrose added to milk
Number of subjects: 267
Study 23438341 — intervention group
Group type: EXPERIMENTAL
Intervention: KAI-1678 (25 mg)
Number of subjects: 23
Study 23438341 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine hydrochloride (700 mg)
Number of subjects: 23
Study 23438341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 21052689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone 1.25 mg/kg
Number of subjects: 32
Study 21052689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone 2.5 mg/kg
Number of subjects: 32
Study 21052689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone 5.0 mg/kg
Number of subjects: 32
Study 21052689 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution (control)
Number of subjects: 32
Study 19125892 — intervention group
Group type: EXPERIMENTAL
Intervention: DAMET-2 program (experimental group)
Number of subjects: 34
Study 19125892 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 19125892 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 17233683 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplementation
Number of subjects: 763
Study 17233683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 763
Study 17233683 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplementation (in subjects without dementia)
Number of subjects: 763
Study 15605872 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor unit number index (MUNIX) in normal subjects
Number of subjects: 0
Study 15605872 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor unit number index (MUNIX) in ALS patients
Number of subjects: 0
Study 15605872 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor unit number index (MUNIX) in weaker muscles
Number of subjects: 0
Study 11131823 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior knowledge with uneven distribution of crossover features
Number of subjects: 0
Study 11131823 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior knowledge with even distribution of crossover features
Number of subjects: 0
Study 11131823 — intervention group
Group type: EXPERIMENTAL
Intervention: Slightly less uneven distribution of crossover features
Number of subjects: 0
Study 11131823 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge benefits learning
Number of subjects: 0
Study 9305486 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 4 weeks
Number of subjects: 221
Study 9305486 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg q.d.s. for 4 weeks
Number of subjects: 221
Study 9305486 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for an additional 4 weeks (total 8 weeks)
Number of subjects: 221
Study 8370191 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 8370191 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine combined with beta blockers and/or long-acting nitrates
Number of subjects: 0
Study 3554490 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg propranolol intravenously twice daily
Number of subjects: 39
Study 3554490 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg propranolol intravenously twice daily
Number of subjects: 39
Study 3554490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3554490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients older than 60 years)
Number of subjects: 39
Study 3554490 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (in patients older than 60 years)
Number of subjects: 39
Study 3554490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients who had surgery on distal colon)
Number of subjects: 39
Study 3554490 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (in patients who had surgery on distal colon)
Number of subjects: 39
Study 30317269 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU treatment
Number of subjects: 80
Study 30317269 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgically treated)
Number of subjects: 80
Study 28059054 — intervention group
Group type: EXPERIMENTAL
Intervention: Families for Health
Number of subjects: 128
Study 28059054 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 128
Study 23489996 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite atrial fibrillation
Number of subjects: 175
Study 23436315 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid acetaminophen preparation (15 mg/kg)
Number of subjects: 15
Study 23436315 — intervention group
Group type: COMPARATOR
Intervention: Solid acetaminophen preparation (15 mg/kg)
Number of subjects: 15
Study 21549065 — intervention group
Group type: EXPERIMENTAL
Intervention: sTREM-1 levels measured by ELISA
Number of subjects: 32
Study 21549065 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count (PLT)
Number of subjects: 32
Study 21549065 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score
Number of subjects: 32
Study 19064624 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 677
Study 19064624 — intervention group
Group type: COMPARATOR
Intervention: chloroquine-sulfadoxine-pyrimethamine
Number of subjects: 677
Study 19064624 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-sulfadoxine-pyrimethamine
Number of subjects: 677
Study 19064624 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 677
Study 16626578 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg subcutaneously, Q12 h, at least twice before CAG)
Number of subjects: 966
Study 16626578 — intervention group
Group type: COMPARATOR
Intervention: UFH (25 mg iv before CAG with additional 65 mg iv if PCI indicated)
Number of subjects: 966
Study 16626578 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 966
Study 16626578 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 966
Study 14597864 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise electrocardiography
Number of subjects: 71
Study 14597864 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole stress echo
Number of subjects: 71
Study 10619579 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (dietary counseling and group support)
Number of subjects: 0
Study 10619579 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8840665 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1721224 — intervention group
Group type: EXPERIMENTAL
Intervention: VVIR pacing
Number of subjects: 6
Study 1721224 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 6
Study 6805000 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin and lithium carbonate
Number of subjects: 28
Study 6805000 — intervention group
Group type: COMPARATOR
Intervention: Placebo and lithium carbonate
Number of subjects: 28
Study 29882634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 11 weeks
Number of subjects: 67
Study 29882634 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in physical exercise habits)
Number of subjects: 67
Study 28656605 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.02, 0.04, 0.08 and 0.16 mg/kg)
Number of subjects: 32
Study 28656605 — intervention group
Group type: COMPARATOR
Intervention: Norditropin® SimpleXx® (0.03 mg/kg)
Number of subjects: 32
Study 26000501 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced information and values clarification regarding prenatal genetic testing
Number of subjects: 710
Study 26000501 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control)
Number of subjects: 710
Study 22498012 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical involvement in 12-step activities
Number of subjects: 0
Study 22498012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford House condition
Number of subjects: 0
Study 22498012 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 0
Study 21668279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing materials (4 different types)
Number of subjects: 4
Study 18711222 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 3527
Study 18711222 — intervention group
Group type: COMPARATOR
Intervention: GFR 45-59 ml/min/1.73 m² BSA
Number of subjects: 3527